001     131738
005     20240229105010.0
024 7 _ |a 10.1016/j.expneurol.2017.09.012
|2 doi
024 7 _ |a pmid:28974375
|2 pmid
024 7 _ |a 0014-4886
|2 ISSN
024 7 _ |a 1090-2430
|2 ISSN
024 7 _ |a altmetric:27041988
|2 altmetric
037 _ _ |a DKFZ-2018-00044
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Seyrantepe, Volkan
|b 0
245 _ _ |a Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
260 _ _ |a Amsterdam [u.a.]
|c 2018
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521450942_7049
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tay-Sachs disease is a severe lysosomal storage disorder caused by mutations in Hexa, the gene that encodes for the α subunit of lysosomal β-hexosaminidase A (HEXA), which converts GM2 to GM3 ganglioside. Unexpectedly, Hexa-/- mice have a normal lifespan and show no obvious neurological impairment until at least one year of age. These mice catabolize stored GM2 ganglioside using sialidase(s) to remove sialic acid and form the glycolipid GA2, which is further processed by β-hexosaminidase B. Therefore, the presence of the sialidase (s) allows the consequences of the Hexa defect to be bypassed. To determine if the sialidase NEU3 contributes to GM2 ganglioside degradation, we generated a mouse model with combined deficiencies of HEXA and NEU3. The Hexa-/-Neu3-/- mice were healthy at birth, but died at 1.5 to 4.5months of age. Thin-layer chromatography and mass spectrometric analysis of the brains of Hexa-/-Neu3-/- mice revealed the abnormal accumulation of GM2 ganglioside. Histological and immunohistochemical analysis demonstrated cytoplasmic vacuolation in the neurons. Electron microscopic examination of the brain, kidneys and testes revealed pleomorphic inclusions of many small vesicles and complex lamellar structures. The Hexa-/-Neu3-/- mice exhibited progressive neurodegeneration with neuronal loss, Purkinje cell depletion, and astrogliosis. Slow movement, ataxia, and tremors were the prominent neurological abnormalities observed in these mice. Furthermore, radiographs revealed abnormalities in the skeletal bones of the Hexa-/-Neu3-/- mice. Thus, the Hexa-/-Neu3-/- mice mimic the neuropathological and clinical abnormalities of the classical early-onset Tay-Sachs patients, and provide a suitable model for the future pre-clinical testing of potential treatments for this condition.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Glycosphingolipids
|2 NLM Chemicals
650 _ 7 |a Neu3 protein, mouse
|0 EC 3.2.1.18
|2 NLM Chemicals
650 _ 7 |a Neuraminidase
|0 EC 3.2.1.18
|2 NLM Chemicals
650 _ 7 |a Hexosaminidase B
|0 EC 3.2.1.52
|2 NLM Chemicals
700 1 _ |a Demir, Secil Akyildiz
|b 1
700 1 _ |a Timur, Zehra Kevser
|b 2
700 1 _ |a Von Gerichten, Johanna
|0 P:(DE-He78)6565c340d78174caba1097b0f275550e
|b 3
|u dkfz
700 1 _ |a Marsching, Christian
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Erdemli, Esra
|b 5
700 1 _ |a Oztas, Emin
|b 6
700 1 _ |a Takahashi, Kohta
|b 7
700 1 _ |a Yamaguchi, Kazunori
|b 8
700 1 _ |a Ates, Nurselin
|b 9
700 1 _ |a Dönmez Demir, Buket
|b 10
700 1 _ |a Dalkara, Turgay
|b 11
700 1 _ |a Erich, Katrin
|b 12
700 1 _ |a Hopf, Carsten
|b 13
700 1 _ |a Sandhoff, Roger
|0 P:(DE-He78)a928ded2085c8911822370cad0b4a728
|b 14
|u dkfz
700 1 _ |a Miyagi, Taeko
|b 15
773 _ _ |a 10.1016/j.expneurol.2017.09.012
|g Vol. 299, no. Pt A, p. 26 - 41
|0 PERI:(DE-600)1466932-8
|n Pt A
|p 26 - 41
|t Experimental neurology
|v 299
|y 2018
|x 0014-4886
909 C O |o oai:inrepo02.dkfz.de:131738
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6565c340d78174caba1097b0f275550e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)a928ded2085c8911822370cad0b4a728
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP NEUROL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G131-20160331
|k G131
|l AG Lipid-Pathobiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G131-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21